| 001 | 1046717 | ||
| 005 | 20251008122909.0 | ||
| 024 | 7 | _ | |a 10.1093/noajnl/vdaf196 |2 doi |
| 024 | 7 | _ | |a 10.34734/FZJ-2025-03929 |2 datacite_doi |
| 037 | _ | _ | |a FZJ-2025-03929 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Stetter, Isabelle |0 0009-0007-1732-5759 |b 0 |
| 245 | _ | _ | |a Prediction of progression-free andoverall survival following temozolomide chemoradiation using FET PET-base,d parameter.s including radiomics in patients with glio blastorna |
| 260 | _ | _ | |a Oxford |c 2025 |b Oxford University Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1759822350_28037 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a supported by the Deutsche Forschungsgemeinschaft project number 428090865/SPP2177 (Norbert Galldiks, Philipp Lohmann, Keith George Ciantar) |
| 520 | _ | _ | |a Background: Early after surgery and completion of first-line radiotherapy with concomitant temozolomide, the prediction of progression-free and overall survival (PFS, OS) is of considerable interest for managing patients with glioblastoma.Methods: Sixty-three newly diagnosed patients with glioblastoma (age range, 19-82 years) who received PET imaging using the radiolabeled amino acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET) after surgery or biopsy and completion of radiotherapy with concomitant temozolomide were evaluated. Static FET PET parameters, that is, maximum and mean tumor-to-brain ratios (TBRmax, TBRmean), metabolic tumor volumes (MTV), and the dynamic FET PET parameters time-to-peak (TTP) and slope were obtained. Additionally, n = 1,303 FET PET radiomics features were extracted per patient, of which 15 robust features were selected for further evaluation based on test-retest analysis. The prognostic values of FET PET parameters and radiomics features were evaluated using receiver-operating-characteristic (ROC) analyses regarding a favorable PFS and OS. Subsequently, univariate and multivariate survival estimates were performed to assess the prognostic value of these parameters in predicting a significantly longer PFS and OS.Results: ROC analyses revealed that static parameters (ie, TBRmax, MTV) and one radiomics feature were the most powerful parameters to predict a significantly longer PFS (all P = .002) and OS (all P ≤ .02). In addition, the dynamic parameter TTP predicted a significantly longer OS (P ≤ .03) but not PFS (P > .05). TBRmax, MTV, and one radiomics feature remained significant in multivariate survival analysis (all P ≤ .03).Conclusion: Our results suggest that FET PET parameters, including radiomics, are highly prognostic in patients with glioblastoma at an early stage of first-line therapy.Keywords: artificial intelligence; glioma; prognosis. |
| 536 | _ | _ | |a 5252 - Brain Dysfunction and Plasticity (POF4-525) |0 G:(DE-HGF)POF4-5252 |c POF4-525 |f POF IV |x 0 |
| 536 | _ | _ | |a DFG project G:(GEPRIS)428090865 - Radiomics basierend auf MRT und Aminosäure PET in der Neuroonkologie (428090865) |0 G:(GEPRIS)428090865 |c 428090865 |x 1 |
| 588 | _ | _ | |a Dataset connected to DataCite |
| 700 | 1 | _ | |a Werner, Jan-Michael |0 0000-0001-7147-4594 |b 1 |
| 700 | 1 | _ | |a Wollring, Michael |0 P:(DE-Juel1)190394 |b 2 |
| 700 | 1 | _ | |a Ceccon, Garry |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Ciantar, Keith George |0 P:(DE-Juel1)203314 |b 4 |u fzj |
| 700 | 1 | _ | |a Stoffels, Gabriele |0 P:(DE-Juel1)131627 |b 5 |
| 700 | 1 | _ | |a Mottaghy, Felix M |0 P:(DE-Juel1)132318 |b 6 |u fzj |
| 700 | 1 | _ | |a Fink, Gereon R |0 P:(DE-Juel1)131720 |b 7 |u fzj |
| 700 | 1 | _ | |a Langen, Karl-Josef |0 P:(DE-Juel1)131777 |b 8 |u fzj |
| 700 | 1 | _ | |a Lohmann, Philipp |0 P:(DE-Juel1)145110 |b 9 |
| 700 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 10 |e Corresponding author |u fzj |
| 773 | _ | _ | |a 10.1093/noajnl/vdaf196 |g Vol. 7, no. 1, p. vdaf196 |0 PERI:(DE-600)3009682-0 |n 1 |p vdaf196 |t Neuro-oncology advances |v 7 |y 2025 |x 2632-2498 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1046717/files/SOA25LT012481.pdf |
| 856 | 4 | _ | |y Restricted |u https://juser.fz-juelich.de/record/1046717/files/Invoice_SOA25LT012481.pdf |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/1046717/files/PDF.pdf |
| 909 | C | O | |o oai:juser.fz-juelich.de:1046717 |p openaire |p open_access |p OpenAPC |p driver |p VDB |p openCost |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)203314 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)131627 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)132318 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)131720 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)131777 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)145110 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)143792 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5252 |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-18 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0112 |2 StatID |b Emerging Sources Citation Index |d 2024-12-18 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOL ADV : 2022 |d 2024-12-18 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0 |0 LIC:(DE-HGF)CCBYNC4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2024-04-03T10:37:56Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2024-04-03T10:37:56Z |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-18 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-18 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2024-04-03T10:37:56Z |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-18 |
| 915 | p | c | |a APC keys set |2 APC |0 PC:(DE-HGF)0000 |
| 915 | p | c | |a DOAJ Journal |2 APC |0 PC:(DE-HGF)0003 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a APC |
| 980 | 1 | _ | |a APC |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::